Axsome Therapeutics, Inc. (AXSM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-30

Key Insights

FDA approval of AUVELITY® for agitation associated with dementia due to Alzheimer's disease represents a significant label expansion into the neurodegenerative disease market, potentially opening a new revenue stream beyond the drug's current indications.
This approval demonstrates successful regulatory progress for Axsome's pipeline and validates the company's therapeutic approach, which could enhance investor confidence in future product development efforts.
The expansion into Alzheimer's-related agitation addresses a substantial unmet medical need affecting millions of patients, positioning AUVELITY® as a potential market leader in this indication and supporting long-term revenue growth potential.

Want the newest filings?

This analysis covers the filing from 2026-04-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-01

Axsome Therapeutics has acquired a selective PDE10A inhibitor called balipodect, which could potentially be used to treat schizophrenia and other neuropsychiatric conditions.
The acquisition of balipodect represents an expansion of Axsome's pipeline into the neuropsychiatric therapeutic area, diversifying the company's drug development portfolio.
The press release suggests this acquisition is a strategic move by Axsome to bolster its position in the neuropsychiatric drug market and leverage its expertise in central nervous system disorders.

Filed: 2026-02-23

Axsome Therapeutics announced its financial results for the three months and fiscal year ended December 31, 2025, providing investors with an update on the company's operations.
The company did not disclose any details about material agreements, leadership changes, or earnings surprises in this filing.
Without further details on the financial performance or key business developments, the significance of this 8-K filing is limited.

Filed: 2026-02-17

Axsome Therapeutics has entered into a settlement agreement with Alkem Laboratories to resolve patent litigation related to its product SUNOSI (solriamfetol). This allows Alkem to sell a generic version of SUNOSI starting in 2040, subject to FDA approval.
The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, indicating regulatory oversight of the deal.
Separate patent litigation related to SUNOSI against another party remains pending, suggesting continued legal uncertainty around the product.

Filed: 2026-01-12

Axsome Therapeutics provided preliminary Q4 and full year 2025 net product revenue figures, indicating continued strong financial performance.
The company did not provide any additional details or commentary on the preliminary results, leaving investors with limited information to assess the significance of the update.
Without further details on product sales, profitability, or guidance, it is difficult to determine the full implications of this announcement for Axsome's future prospects.

Filed: 2025-12-31

Axsome Therapeutics received FDA acceptance and priority review for its supplemental New Drug Application for the treatment of Alzheimer's Disease Agitation, potentially accelerating the drug's path to market.
The company also received formal pre-NDA meeting minutes from the FDA for its planned NDA submission for AXS-12 in narcolepsy, indicating progress in its pipeline development.
These two key regulatory developments suggest Axsome's pipeline is advancing and could lead to potential new product approvals, which could drive future revenue growth and investor interest.

Other reports for Axsome Therapeutics, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.